Hormone Insight

Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.

Hormone Insight is a education podcast hosted by FWA, with 23 episodes on record and a Required Pod Score of 80.

FWA hosts Hormone Insight, a education show with 23 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Hormone Insight

  SURMOUNT-1: 20% weight loss | Hormone Insight Podcast

  Oct 5, 20264 min

  Does once-weekly tirzepatide reduce body weight in adults with obesity? In adults with obesity, once-weekly tirzepatide reduced body weight substantially more than placebo over 72 weeks, by up to about 21%. Randomized trial · NEJM 2022 Reference: Jastreboff AM, Aronne LJ, Ahmad NN. N Engl J Med. 2022; PMID:35658024 Chapters 0:00 Intro 0:38 The trial 3:12 My take 3:48 Outro Read the structured trial summary at https://hormoneinsight.com/ AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. Explore Hormone Insight: Website: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  ListenShow Notes
• 

  Hormone Insight

  POLY-HF: One pill for heart failure? | Hormone Insight Podcast

  Oct 4, 20264 min

  Can a polypill improve heart-failure treatment? Combining three heart-failure medicines into one daily capsule improved six-month MRI-measured ejection fraction versus actively optimized separate medicines. Secondary clinical-event findings are encouraging but do not establish a mortality benefit. Randomized trial · Nature Medicine 2026 Reference: Pandey A, Keshvani N, Rizvi SK, et al. Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial. Nat Med. 2026;32:2933–2940. doi:10.1038/s41591-026-04504-5. PMID:42393373. Chapters 0:00 Intro 0:38 The trial 3:23 My take 4:01 Outro Read the structured trial summary at hormoneinsight.com This podcast is intended for healthcare professionals only. It is educational and is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. AI narration disclosure: This episode uses AI-generated narration. For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  ListenShow Notes
• 

  Hormone Insight

  SUMMIT: Tirzepatide in HFpEF | Hormone Insight Podcast

  Oct 3, 20264 min

  Does tirzepatide improve cardiovascular outcomes and quality of life in patients with heart failure with preserved ejection fraction and obesity? In patients with heart failure with preserved ejection fraction and obesity, tirzepatide reduced the risk of cardiovascular death or worsening heart failure and improved health status compared with placebo. Randomized trial · NEJM 2025 Reference: Packer M, Zile MR, Kramer CM. N Engl J Med. 2025; PMID: 39555826 Chapters 0:00 Intro 0:38 The trial 3:27 My take 4:02 Outro Read the structured trial summary at hormoneinsight.com This podcast is intended for healthcare professionals only. It is educational and is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. AI narration disclosure: This episode uses AI-generated narration. For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  ListenShow Notes
• 

  Hormone Insight

  EMPA-KIDNEY: SGLT2 for all CKD | Hormone Insight Podcast

  Oct 2, 20265 min

  Does empagliflozin help patients with chronic kidney disease? In patients with chronic kidney disease at risk of progression, empagliflozin reduced the risk of kidney-disease progression or cardiovascular death compared with placebo by about 28%. Randomized trial · NEJM 2023 Reference: The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine. 2023;388(2):117-127. doi:10.1056/NEJMoa2204233. PMID:36331190. Chapters 0:00 Intro 0:38 The trial 3:33 My take 4:11 Outro Read the structured trial summary at hormoneinsight.com This podcast is intended for healthcare professionals only. It is educational and is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. AI narration disclosure: This episode uses AI-generated narration. For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  ListenShow Notes
• 

  Hormone Insight

  FLOW: Semaglutide and the kidney | Hormone Insight Podcast

  Oct 1, 20265 min

  Does semaglutide reduce kidney and cardiovascular risks in patients with type 2 diabetes and chronic kidney disease? In patients with type 2 diabetes and chronic kidney disease, once-weekly semaglutide 1.0 mg reduced the risk of major kidney disease events and death from cardiovascular causes compared with placebo (about 24% lower primary-outcome risk). Randomized trial · NEJM 2024 Reference: Perkovic V, Tuttle KR, Rossing P. N Engl J Med. 2024; PMID: 38785209. Chapters 0:00 Intro 0:38 The trial 3:58 My take 4:35 Outro AI narration disclosure: This episode uses AI-generated narration. For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.